

**U-M Institutional Biosafety Committee
Minutes**

Approved at the July 17, 2026, IBC Meeting

Meeting Information:

Date: Friday, June 19, 2026

Time: 1:15-2:30 p.m.

Location: Via conference call (Zoom)

Voting Members Present: Pamela Bennett-Baker, Matt Chapman, Chris Fenno, Sheya Jones, Huiira Kopera, Joyce Lai, Daniel Lawrence, Patrick Lester, Akira Ono, Alex Rickard, Jackie Shields

Voting Members Absent: Wanlu Du, Tom Lanigan, Jon Oscherwitz, Stephen Rapundalo, Andrew Tai, John Thomas, Fei Wen, Christiane Wobus

Alternate Members Present: Jessica Bunn (alt. for Jones), Crystal O'Donnell (alt. for Jones)

IBC Staff Members Present: Jen Harley, Michael Santiago-Castro, Alicia Trombley

Guests Present: Carolyn Kuenz, Eric Robertson, Nicoleen Boyle, Andrew Kennedy, Jonah Lee, Anne Devlin, Ingrid Walstad-Terpak, Em SeGraves, Diane Lehman

The meeting was called to order at: 1:15 p.m.

The meeting was adjourned at: 1:37 p.m.

Agenda Items:

1. Updates from the Chair – Chris Fenno (in place of Christiane Wobus)

Dr. Fenno and Jackie Shields thanked Akira Ono, Dan Lawrence, and John Thomas for their service, noting that this was their final IBC meeting before their terms end on July 1, and offered special recognition to Dr. Ono for ten years of service on the committee.

2. Consideration of minutes from the previous meeting

The committee reviewed the minutes from the May 15, 2025, meeting. There were no changes recommended.

Motion: Matt Chapman moved to approve the minutes.

Second: Sheya Jones seconded the motion.

Vote: All in favor.

3. Biosafety Officer Report – Sheya Jones

There were no reportable incidents this month.

4. Conflict of interest disclosure opportunity

Dr. Fenno asked committee members whether they or their labs were involved with, or were in conflict with, financially or otherwise, any items on today's agenda.

1. Dan Lawrence indicated a conflict with application IBCA00000842_AR03 for Dr. Eitzman.

5. Applications for committee action

The following BSL1 application was considered and voted upon separately by the committee due to a conflict of interest.

34. IBCA00000842_AR03

Eitzman, Daniel – Renewal

Current approval: ABSL1 (transgenic mice). No work involving rDNA, infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

Motion: Sheya Jones moved to approve the (1) applications listed above, at the containment levels agreed upon, contingent upon any contingencies noted above.

Second: Matt Chapman seconded the motion.

Vote: All in favor, with Dan Lawrence recused.

BSL2 Applications

The following BSL2 applications were considered by the committee and voted upon:

1. IBCA00000013_AR06

Roberts, Michael – Amendment

Current approval: BSL1 (AAV vectors); BSL2 (TTX, Cholera toxin subunit B); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors or CTB). No work involving infectious agents, animal-derived substances, or plants.

Changes: Added work with rabies vectors (BSL2) with administration to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable review from one reviewer.

2. IBCA00000073_AR24

Xu, Zhen – Amendment

Current approval: BSL1 (human-derived substances: decontaminated human skullcap), BSL2 (human-derived substances; animal-derived substances from swine and ruminants); ABSL1 (rodents administered rDNA-modified animal cells; pigs administered animal-derived substances or human-derived substances: decontaminated human skullcap); ABSL2 for the duration (mice administered human-derived substances). No work involving infectious agents, biological toxins, or plants.

Changes: Added additional work with human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

3. IBCA00000160_AR05

Humes, H – Renewal

Current approval: BSL2 (E. coli (pathogenic strains)); BSL2 (LPS); BSL2 (human-derived substances); BSL2 (animal-derived substances: swine); ABSL1 (swine administered LPS); ABSL2 for the duration

(swine administered E. coli (pathogenic strains), human-derived substances, or animal-derived substances: swine). No work involving rDNA or plants.

Changes: Updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

4. IBCA00000266_AR04

Goldman, Daniel – Amendment

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (AAV vectors with growth control genes); ABSL1 (transgenic mice and zebrafish); ABSL1 (mice administered AAV vectors; zebrafish administered vectorless systems or plasmid vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: Added work with lentivirus vectors (BSL2) and human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application and favorable re-review from one reviewer.

5. IBCA00000304_AR07

Shikanov, Ariella – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances and animal-derived substances from ruminants and non-human primates); ABSL1 (transgenic mice); ABSL1 (mice administered animal-derived substances from ruminants or rDNA-modified rodent cells); ABSL2 for the duration (mice administered human-derived substances, rDNA-modified human-derived substances, or rDNA-modified non-human primate cells). No work involving infectious agents, biological toxins, or plants.

Changes: Added work with animal-derived substances from swine (BSL2) with administration to mice (ABSL1). Removed work with rDNA.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable re-review from one reviewer.

6. IBCA00000323_AR08

Cai, Dawen – Amendment

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (MoLV, lentivirus, and rabies virus vectors); BSL1 (Cholera toxin subunit B); BSL2 (Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice and fruit flies); ABSL1 (mice and fruit flies administered plasmid vectors; mice administered rabies, AAV, or retrovirus vectors, Diphtheria toxin, or Cholera toxin subunit B); ABSL2 for 3 days (mice administered retrovirus vectors via Category 2 routes of administration). No work involving infectious agents, animal-derived substances, or plants.

Changes: Added new gene elements in plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

7. IBCA00000341_AR07

Shi, Jiaqi – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells or vectorless systems); ABSL2 for the duration (mice administered human-derived

substances or rDNA-modified human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

8. IBCA00000385_AR12

Cone, Roger – Renewal

Current approval: BSL1 (plasmid, AAV, and baculovirus vectors); BSL2 (lentivirus and rabies virus vectors; AAV vectors with growth control genes); BSL2 (tetrodotoxin, Cholera toxin, Pertussis toxin, and Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered AAV or rabies vectors; mice administered Diphtheria toxin); ABSL2 for 3 days (mice administered AAV vectors with growth control genes via Cat 2 ROAs). No work involving infectious agents, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application and favorable re-review from one reviewer.

9. IBCA00000432_AR04

Bailey, Ryan – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, human- or animal-derived substances, animals or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. Approval is contingent upon minor edits being made to the application.

10. IBCA00000453_AR18

Chen, Yuqing – Amendment

Current approval: BSL1 (plasmid and AAV vectors; vectorless systems); BSL2 (adenovirus, lentivirus, and MoLV vectors); BSL2 (RG2 bacteria); BSL2 (LPS and Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic rodents and rabbits); ABSL1 (mice administered Diphtheria toxin, vectorless systems, or plasmid vectors; mice and rabbits administered AAV vectors, LPS or rDNA modified animal cells; rats administered plasmid vectors or rDNA modified animal cells); ABSL2 for 3 days (rodents and rabbits administered adenovirus vectors; rabbits and mice administered AAV vectors with growth control genes; rabbits administered retrovirus vectors); ABSL2 for the duration (rodents and rabbits administered rDNA modified human cells, mice and rabbits administered human-derived substances, mice and rabbits administered RG2 bacteria). No work involving animal-derived substances or plants.

Changes: Added administration of vectorless systems to rabbits (ABSL1) and administration of rDNA-modified human-derived substances to rats (ABSL2 for the duration).

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

11. IBCA00000587_AR05

Zhang, Yan – Renewal

Current approval: BSL1 (vectorless systems, AAV, and plasmid vectors); BSL2 (lentiviral, MoLV

vectors, and plasmid vectors in RG2 host); BSL2 (Neisseria meningitides); BSL2 (human-derived substances). No work involving biological toxins, animal-derived substances, animals or plants.

Changes: Added additional plasmid and AAV vectors (BSL1) and additional human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

12. IBCA00000657_AR04

Giger, Roman – Renewal

Current approval: BSL1 (plasmid and AAV vectors; vectorless systems); BSL2 (retrovirus vectors and AAV vectors with growth control genes); BSL1 (Cholera toxin subunit B); BSL2 (Diphtheria toxin, LPS, TTX); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered retrovirus vectors, AAV vectors, LPS, Cholera toxin subunit B, or Diphtheria toxin; rats administered Cholera toxin subunit B); ABSL2 for 3 days (rats administered AAV vectors or rDNA modified animal cells); ABSL2 for the duration (mice administered human-derived substances). No work involving infectious agents, animal-derived substances, or plants.

Changes: Changed the containment level for rats administered AAV vectors by category 1 routes of administration and rDNA modified animal cells to ABSL1.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application and favorable re-review from two reviewers.

13. IBCA00000695_AR05

Koutmou, Kristin – Amendment

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (Coronavirus and Epstein-Barr virus); BSL2 (human-derived substances). No work involving biological toxins, animal-derived substances, animals or plants.

Changes: Added work with *N. crassa* (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

14. IBCA00000720_AR04

Yu, Lei – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral and MoLV vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable re-review from one reviewer.

15. IBCA00000773_AR09

Zemans, Rachel – Renewal

Current approval: BSL1 (AAV vectors, plasmid vectors, and vectorless systems); BSL2 (adenoviral, AAV, and lentiviral vectors); BSL2 (RG2 bacteria and Influenza H1N1 virus); BSL2 (Diphtheria toxin and LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered vectorless systems, Diphtheria toxin, or LPS); ABSL2 for 3 days (mice administered adenoviral or AAV

vectors); ABSL2 for the duration (mice administered human-derived substances or RG2 infectious agents). No work involving animal-derived substances or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

16. IBCA00000775_AR10

Seeley, Randy – Renewal

Current approval: BSL1 (plasmid, AAV vectors, and vectorless systems); BSL2 (lentiviral, adenoviral, and AAV vectors with growth control genes); BSL2 (LPS, Diphtheria toxin); BSL2 (human-derived substances); ABSL1 (transgenic rodents); ABSL1 (rodents administered vectorless systems, AAV vectors, or LPS; rodents administered lentivirus or adenovirus intracranially; mice administered rabies or pseudorabies viral vectors); ABSL2 for 3 days (rodents administered lentiviral, adenoviral, or AAV vectors with growth control genes). No work involving infectious agents, animal-derived substances, or plants.

Changes: Removed work with lentivirus and adenovirus vectors.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

17. IBCA00000850_AR09

Prasov, Lev – Amendment

Current approval: BSL1 (vectorless systems, AAV, cosmid, and plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances from ruminants and swine); ABSL1 (transgenic mice); ABSL1 (mice administered lentiviral or AAV vectors). No work involving infectious agents, biological toxins, or plants.

Changes: Added additional work with vectorless systems (BSL1) with administration to mice (ABSL1) and updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

18. IBCA00000865_AR05

Colacino, Justin – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added work with LPS and Cholera toxin (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

19. IBCA00000899_AR05

Baldrige, Ryan – Renewal

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentivirus vectors); BSL2

(human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Added new gene elements in plasmid vectors and updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

20. IBCA00000931_AR09

Morrissey, James – Renewal

Current approval: BSL1 (plasmid and phage vectors); BSL2 (lentiviral vectors); BSL1 (animal-derived substances from ruminants and swine); BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, or plants.

Changes: Added additional plasmid vectors (BSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate.

21. IBCA00000972_AR10

Burgess, Christian – Amendment

Current approval: BSL1 (canine adenovirus vectors and AAV vectors); BSL2 (rabies virus vectors and AAV vectors with toxic genes); BSL1 (cholera toxin subunit B); ABSL1 (transgenic mice); ABSL1 (mice administered cholera toxin subunit B, rabies virus vectors, AAV vectors, or canine adenovirus vectors). No work involving infectious agents, human- or animal-derived substances, or plants.

Changes: This is an amendment adding work with Diphtheria toxin (BSL2) with administration to mice.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application, favorable review from one reviewer, and favorable re-review by two reviewers.

22. IBCA00001214_AR03

Reed, Matt – Amendment

Current approval: BSL2 (human-derived substances). No work involving rDNA, infectious agents, biological toxins, animal-derived substances, animals or plants.

Changes: Added additional work with human-derived substances (BSL2) and updated risk mitigation practices.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

23. IBCA00001441_AR05

Nagrath, Sunitha – Renewal

Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (HIV); BSL1 (animal-derived substances from swine); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL2 for the duration (mice administered human-derived substances or rDNA-modified human-derived substances). No work involving biological toxins or plants.

Changes: Added administration of rDNA-modified animal cells to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable re-review from one reviewer.

24. IBCA00001685_AR10**Killian, Megan – Renewal**

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (Botulinum neurotoxins); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered AAV vectors or Botulinum neurotoxins). No work involving infectious agents, animal-derived substances, or plants.

Changes: Added new gene elements in plasmid vectors (BSL1) and updated risk mitigation practices (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application.

25. IBCA00001929_AR01**Fahim, Abigail – Renewal**

Current approval: BSL1 (plasmid, phage, and AAV vectors); BSL2 (lentivirus vectors); BSL2 (human-derived substances); BSL1 (animal-derived substances: bovine); ABSL1 (transgenic mice); ABSL1 (mice administered lentivirus and AAV vectors). No work involving infectious agents, biological toxins, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable review from two reviewers.

26. IBCA00002011_AR05**Surface, Lauren – Amendment**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered rDNA-modified animal cells). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added work with additional human-derived substances (BSL2).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate.

27. IBCA00002760_AR04**Wolf-Fortune, Sonya – Amendment**

Current approval: BSL1 (plasmid vectors and vectorless systems); BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving infectious agents, animal-derived substances, or plants.

Changes: Added new gene elements in vectorless systems (BSL1) with administration to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application and favorable review from one reviewer.

28. IBCA00002852_AR01**Affinati, Alison – Amendment**

Current approval: BSL1 (plasmid and AAV vectors); BSL2 (adenovirus, pseudorabies, rabies, and AAV vectors with growth control genes); BSL2 (tetanus toxin); ABSL1 (transgenic mice); ABSL1 (mice administered AAV, plasmid, adenovirus, rabies, or pseudorabies vectors). No work involving infectious agents, human- or animal-derived substances, or plants.

Changes: Added work with LPS (BSL2) with administration to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable re-review from one reviewer.

29. IBCA00002862_AR02

Schuler, Chase – Amendment

Current approval: BSL1 (plasmid vectors); BSL2 (lentiviral vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Changes: Added work with Cholera toxin (BSL2) with administration to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon favorable re-review from one reviewer.

30. IBCA00002902_AR02

Lifshitz, Jonny – Amendment

Current approval: Current approval: BSL2 (LPS); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered LPS). No work involving rDNA, infectious agents, animal-derived substances, or plants.

Changes: Added administration of LPS to rats (ABSL1).

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

31. IBCA00003169

Brown, David - Initial Application

Proposed: BSL1 (plasmid and AAV vectors); BSL2 (human-derived substances); ABSL1 (transgenic mice); ABSL1 (mice administered plasmid vectors; rodents administered AAV vectors); ABSL2 for the duration (mice administered human-derived substances). No work involving infectious agents, biological toxins, animal-derived substances, or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application and favorable re-review from two reviewers.

32. IBCA00003170_AR01

Su, Yajuan – Amendment

Current approval: ABSL1 (transgenic mice). No work involving rDNA, infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: Added work with Diphtheria toxin (BSL1) and Cholera toxin subunit B (BSL1) with administration to mice (ABSL1), work with AAV vectors (BSL1) with administration to mice (ABSL1), and work with rabies virus vectors (BSL2) with administration to mice (ABSL1).

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 and BSL2 containment and that BSL2 risk mitigation practices are likewise appropriate. The proposed animal housing containment level is considered appropriate. Approval is contingent upon minor edits being made to the application and favorable re-review from three reviewers.

Motion: Sheya Jones motioned to approve the (32) IBC applications listed above at the containment levels agreed upon, contingent on satisfactory completion of a laboratory inspection in the past year and upon any other contingencies noted above.

Second: Akira Ono seconded the motion.

Vote: All in favor.

BSL1 Applications

The following BSL1 applications were considered by the committee and voted upon.

33. IBCA00000542_AR03

Pletcher, Scott – Renewal

Current approval: BSL1 (plasmid vectors); ABSL1 (transgenic fruit flies). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

34. *This application was handled separately due to a conflict of interest.*

35. IBCA00000880_AR03

Vecchiarelli, Anthony – Renewal

Current approval: BSL1 (plasmid vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, animals or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

36. IBCA00001769_AR02

Yadlapalli, Swathi – Renewal

Current approval: BSL1 (plasmid vectors); ABSL1 (transgenic fruit flies). No work involving infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment. The proposed animal housing containment level is considered appropriate.

37. IBCA00002416_AR02

Stern, Tomer – Renewal

Current approval: ABSL1 (transgenic mice and flies). No work involving rDNA, infectious agents, biological toxins, human- or animal-derived substances, or plants.

Changes: No major changes.

Consensus: The committee agreed with the reviewers that the proposed animal housing containment level is considered appropriate.

38. IBCA00003209

Cichewicz II, Robert - Initial Application

Proposed: BSL1 (phage vectors). No work involving infectious agents, biological toxins, human- or animal-derived substances, animals or plants.

Consensus: The committee agreed with the reviewers that the described work is appropriate for BSL1 containment.

Motion: Sheya Jones motioned to approve the (5) IBC applications listed above at the containment levels agreed upon.

Second: Akira Ono seconded the motion.

Vote: All in favor

6. Matters Arising

There were no matters arising.